BioNTech's Pumitamig Heads to ASCO With Everything to Prove

BioNTech faces pivotal ASCO readout on Pumitamig amid stock weakness, analyst split, and heavy R&D spending. Phase 2 lung cancer data could make or break its oncology push.

When BioNTech’s abstracts for the American Society of Clinical Oncology (ASCO) meeting dropped on May 21, the market got its first look at Phase?2 data for Pumitamig. The full presentation follows on May?29 in Chicago. For a company trying to pivot from pandemic windfall to oncology powerhouse, this is the moment the narrative either gains real traction or stalls.

The stock closed Thursday at €78.30, down 16.52% over the past month and 5.09% since January. The chart shows a stock that has been bleeding, trading 9.53% below its 200-day moving average and just 8% above its 52-week trough. Technical weakness is one thing; what worries some analysts is whether the pipeline can justify the valuations still embedded in the shares.

Bernstein SocGen started coverage with a Market Perform rating and a $96 price target, well below the Street’s average. The firm sees the market as overly optimistic on Pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A. Bernstein’s risk-adjusted peak sales forecast for the oncology pipeline sits a full 43% below the consensus estimate. The reasoning: similar bispecific approaches have historically struggled to demonstrate a statistically significant overall survival benefit, making regulatory approval and commercial uptake far from assured.

Not everyone is that cautious. Bank of America keeps a Buy rating with a $125 target, H.C. Wainwright is at $130, and Canaccord goes as high as $158. Leerink, by contrast, sees fair value at just $94. The spread is extreme, reflecting a market that cannot agree on whether BioNTech’s oncology push will succeed or fizzle.

Pumitamig is being tested in the ROSETTA-Lung-02 study alongside Bristol Myers Squibb in first-line non-small cell lung cancer, directly against Merck’s Keytruda with chemotherapy. That is a tough benchmark, and the Phase?2 portion now under review offers the first real public read on whether the drug can compete. BioNTech also has Pumitamig trials running in liver, glioblastoma, pancreatic, and renal cell cancers, but lung cancer is the headline.

The competitive backdrop is getting tighter. At ASCO, new data are also expected from a Pfizer and 3SBio candidate in the same bispecific PD-L1/VEGF-A class. For BioNTech, efficacy, safety, and the ability to combine with standard therapy will all be under the microscope.

Financially, the company remains well?funded but under pressure. First-quarter revenue came in at €118.1?million, missing the €171?million consensus and down sharply from €182.8?million a year ago. The loss per share widened to €1.95 from €1.79, driven by heavy R&D spending and declining COVID?19 vaccine sales. Yet the balance sheet offers ample cushion: €16.8?billion in cash and equivalents (roughly $19.6?billion) and negligible debt at a 0.02 leverage ratio. A $1?billion share buyback programme, authorised through May?2027, adds support but does not substitute for clinical progress.

Institutional investors are still placing bets. Leonteq Securities built a new position of 27,427 shares in the fourth quarter, worth about $2.6?million. Bank of America and Dodge & Co also raised their stakes. That is not a blanket endorsement, but it suggests long?term players remain engaged despite the stock’s slide.

BioNTech has laid out a roadmap of seven late?stage oncology data readouts this year and aims to have 15 Phase?3 studies running by year?end. The ASCO presentation is the first big checkpoint. Until the next quarterly report, the Pumitamig data will set the tone. If they are strong, the pipeline narrative gains weight. If not, the cash pile alone may not be enough to pull the shares out of their rut.